Fig. 6
IGF2BP2 activates the PI3K-Akt signaling pathway through mediating the m6A modification of FLT4. A Fluorescent probe assay for detecting RNA levels of FLT4 in focal endothelial cells of LUAD patients with high or low CD34 expression. Bar, 50 μm. B Multiplex immunofluorescence assay for measuring protein levels of FLT4 in focal endothelial cells of LUAD patients with high or low CD34 expression. Bar, 50 μm. C Molecular docking for predicting the docking potential of IGF2BP2 protein with mRNA of FLT4. D Multiplex immunofluorescence assay for verifying protein levels of IGF2BP2 and RNA levels of FLT4 in focal endothelial cells of LUAD patients with high or low CD34 expression. Bar, 50 μm. E, F The m.6A levels of FLT4 in A549 and NCI-H1299 cells after transfection with si-NC or si-IGF2BP2. G, H IGF2BP2 protein levels in A549 and NCI-H1299 cells with si-NC or si-IGF2BP2 transfection. I-L FLT4, PI3K, and AKT expression levels in A549 and NCI-H1299 cells with si-NC or si-IGF2BP2 transfection. M The diagram for IGF2BP2-mediated FLT4-PI3K-Akt signaling pathway in regulating angiogenesis during LUAD. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001